v3.26.1
SEGMENT REPORTING (Tables)
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
SCHEDULE OF INFORMATION RELATED TO OPERATIONS OF REPORTABLE OPERATING SEGMENTS

The following table presents information about the Company’s reportable segments for the years ended December 31, 2025 and 2024:

 

   2025  2024
   Year ended
   December 31
   2025  2024
       
Revenue from biotechnology activity   -    - 
Cost related to biotechnology activity (*)   (169)   - 
Salaries and related expenses related to biotechnology activity   

(157

)     
Operating loss from Biotechnology activity   (326)   - 
           
Revenue from renewable energy projects   -    - 
Cost related to renewable energy projects (**)   (340)   - 
Operating loss from renewable energy projects   (340)   

-

 
           
Professional services   (1,727)   (1,791)
Share base compensation   (2,386)   (1,055)
Change in fair value of contingent consideration   

1,136

      
Depreciation   (1)   - 
Other general and administrative expenses   (586)   (437)
Total Operating loss   (4,230)   (3,283)
           
Interest of loans   (77)   - 
Financing expenses, net   (1,468)   (252)
Other income   1,811    428 
Changes in fair value of investments measured under the fair value option   351    (1,212)
Net loss before tax   (3,613)   (4,319)
Income taxes   18    - 
Net loss   (3,595)   (4,319)

 

(*)Costs related to biotechnology activity primarily consist of subcontractors engaged in research and development activities.
(**)Costs related to renewable energy projects primarily consist of expenses incurred for subcontractors providing professional services.
SCHEDULE OF INFORMATION ON LONG LIVED ASSETS

The following table presents the locations of the Company’s long-lived assets as of December 31, 2025 and 2024:

 

   2025  2024
   Year ended December 31
   2025  2024
       
Israel   4,453    - 
United States   16    8 
Italy   

725

    

-

 
Property, plant and equipment and ROU assets   5,194    8